Tag - DTCFF

Executive Moves

Defence appoints Dr. Amie Phinney as president and CEO

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Dr. Amie Phinney, PhD, MBA, as president and CEO, effective August 1, 2026. Sébastien Plouffe, founder and CEO, will assume the position of executive...

August 6, 2026

Developments

Defence expands ADC platform with analytical and cellular testing

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has announced the expansion of internal capabilities to execute critical stages of its ACCUM-enabled antibody drug conjugates (ADC) development pipeline. According...

May 19, 2026

Developments

Defence opens first U.S. laboratory

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) announced that it has opened its first U.S.-based laboratory in the Boston-Cambridge area. According to Defence, the new laboratory will allow the company to...

June 2, 2025

Developments

Defence announces receipt of NOL for Phase I trial of anti-cancer molecule

Defence Therapeutics (CSE:DTC; OTCQB:DTCFF; FSE:DTC) announced that it has received a “no objection letter” (NOL) from Health Canada authorizing the company to proceed with a Phase I trial of intratumoral administration...

July 8, 2024

Tag - DTCFF

Defence appoints Dr. Amie Phinney as president and CEO

Defence expands ADC platform with analytical and cellular testing

Defence opens first U.S. laboratory

Defence announces receipt of NOL for Phase I trial of anti-cancer molecule

Subscribe